BIOMAT Database Logo BIOMAT Database Logo

The effect of ovine corticotrophin releasing factor (oCRF), bromocriptine and TRH on the secretion of ACTH and alpha-MSH in Nelson's syndrome and Cushing's disease. 1986

R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins

The circulating levels of ACTH and alpha-melanocyte stimulating hormone (alpha-MSH) were measured in 9 patients with Nelson's syndrome after the administration of saline, ovine corticotrophin releasing factor (oCRF), bromocriptine or TRH. The concentrations of ACTH were grossly elevated and alpha-MSH levels ranged from undetectable to higher than the normal range. In seven of eight subjects there was a rapid corticotrophic response, but no change in the alpha-MSH level, following oCRF. This response was delayed in one subject. Following oCRF injection, the plasma oCRF profile was variable but circulating oCRF was detectable even at the end of the experiment in all cases. There was no significant change in circulating ACTH or alpha-MSH following either bromocriptine or TRH. Cultured tumour cells from one case of Cushing's disease showed a corticotrophic response but no change in alpha-MSH to oCRF and the response was enhanced by vasopressin. Bromocriptine added to the same tumour depressed ACTH secretion without affecting the output of alpha-MSH. The present data suggest that the tumours in these subjects are responsive to oCRF and arise from corticotrophs rather than melanotrophs.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009074 Melanocyte-Stimulating Hormones Peptides with the ability to stimulate pigmented cells MELANOCYTES in mammals and MELANOPHORES in lower vertebrates. By stimulating the synthesis and distribution of MELANIN in these pigmented cells, they increase coloration of skin and other tissue. MSHs, derived from pro-opiomelanocortin (POMC), are produced by MELANOTROPHS in the INTERMEDIATE LOBE OF PITUITARY; CORTICOTROPHS in the ANTERIOR LOBE OF PITUITARY, and the hypothalamic neurons in the ARCUATE NUCLEUS OF HYPOTHALAMUS. MSH,Melanocyte Stimulating Hormone,Melanocyte-Stimulating Hormone,Melanophore Stimulating Hormone,Melanotropin,MSH (Melanocyte-Stimulating Hormones),Melanophore-Stimulating Hormone,Hormone, Melanocyte Stimulating,Hormone, Melanocyte-Stimulating,Hormone, Melanophore Stimulating,Melanocyte Stimulating Hormones,Stimulating Hormone, Melanocyte,Stimulating Hormone, Melanophore
D009347 Nelson Syndrome A syndrome characterized by HYPERPIGMENTATION, enlarging pituitary mass, visual defects secondary to compression of the OPTIC CHIASM, and elevated serum ACTH. It is caused by the expansion of an underlying ACTH-SECRETING PITUITARY ADENOMA that grows in the absence of feedback inhibition by adrenal CORTICOSTEROIDS, usually after ADRENALECTOMY.
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Effect of ovine corticotrophin releasing factor, bromocriptine, and dopamine on release of ACTH and beta-endorphin in a patient with Cushing's disease.
May 1985, Acta endocrinologica,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Effect of adrenaline on basal and ovine corticotrophin-releasing factor-stimulated ACTH secretion in man.
January 1987, The Journal of endocrinology,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Bromocriptine in Nelson's syndrome and Cushing's disease.
October 1976, Lancet (London, England),
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Dexamethasone inhibits ovine corticotrophin-releasing factor (oCRF), arginine vasopressin (AVP), and oCRF + AVP stimulated release of ACTH during the last third of pregnancy in the sheep fetus.
June 1987, Canadian journal of physiology and pharmacology,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
ACTH secretory responsiveness of pituitary adrenotroph cell tumor to adrenocorticotropin-releasing factor in Cushing's disease and Nelson's syndrome.
June 1986, Experimental and clinical endocrinology,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept.
January 2004, Drugs in R&D,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease.
June 1989, Acta endocrinologica,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.
August 1980, The Journal of clinical endocrinology and metabolism,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
In vitro secretion of ACTH, beta-endorphin and beta-lipotropin in Cushing's disease and Nelson's syndrome.
January 1980, Hormone research,
R R Abraham, and E A Campbell, and B Gillham, and A J Thody, and A R Altaher, and A Prysor-Jones, and V Wynn, and M T Jones, and J Jenkins
Pituitary adenomas that caused Cushing's disease or Nelson's syndrome are not responsive to ovine corticotropin-releasing factor in vitro.
February 1983, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!